Skip navigation

Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12128/19630
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJazowiecka-Rakus, Joanna-
dc.contributor.authorHadryś, Agata-
dc.contributor.authorRahman, Masmudur M.-
dc.contributor.authorMcFadden, Grant-
dc.contributor.authorFidyk, Wojciech-
dc.contributor.authorChmielik, Ewa-
dc.contributor.authorPaździor, Marlena-
dc.contributor.authorGrajek, Maciej-
dc.contributor.authorKozik, Violetta-
dc.contributor.authorSochanik, Aleksander-
dc.date.accessioned2021-03-23T12:53:13Z-
dc.date.available2021-03-23T12:53:13Z-
dc.date.issued2021-
dc.identifier.citation"Cancers" 2021, iss. 6, art. no. 1394pl_PL
dc.identifier.issn2072-6694-
dc.identifier.urihttp://hdl.handle.net/20.500.12128/19630-
dc.description.abstractPancreatic ductal adenocarcinoma (PDAC) is a weakly immunogenic fatal neoplasm. Oncolytic viruses with dual anti-cancer properties—oncolytic and immune response-boosting effects—have great potential for PDAC management. Adipose-derived stem cells (ADSCs) of mesenchymal origin were infected ex vivo with recombinant myxoma virus (MYXV), which encodes murine LIGHT, also called tumor necrosis factor ligand superfamily member 14 (TNFSF14). The viability and proliferation of ADSCs were not remarkably decreased (1–2 days) following MYXV infection, in sharp contrast to cells of pancreatic carcinoma lines studied, which were rapidly killed by the infection. Comparison of the intraperitoneal (IP) vs. the intravenous (IV) route of ADSC/MYXV administration revealed more pancreas-targeted distribution of the virus when ADSCs were delivered IP to mice bearing orthotopically injected PDAC. The biodistribution, tumor burden reduction and anti-tumor adaptive immune response were examined. Bioluminescence data, used to assess the presence of the luciferase-tagged virus after IP injection, indicated enhanced trafficking into the pancreata of mice bearing orthotopically-induced PDAC, as compared to tumor-free animals, resulting in extended survival of the treated PDAC-seeded animals and in the boosted expression of key adaptive immune response markers. We conclude that ADSCs pre-loaded with transgene-armed MYXV and administered IP allow for the effective ferrying of the oncolytic virus to sites of PDAC and mediate improved tumor regression.pl_PL
dc.language.isoenpl_PL
dc.rightsUznanie autorstwa 3.0 Polska*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/pl/*
dc.subjectadipose tissue-derived stem cells (ADSCs)pl_PL
dc.subjectmesenchymal stem cellspl_PL
dc.subjectoncolytic viruspl_PL
dc.subjectmyxoma viruspl_PL
dc.subjectoncolytic virotherapypl_PL
dc.subjectpancreatic ductal adenocarcinomapl_PL
dc.titleMyxoma virus expressing LIGHT (TNFSF14) pre-loaded into adipose-derived mesenchymal stem cells is effective treatment for murine pancreatic adenocarcinomapl_PL
dc.typeinfo:eu-repo/semantics/articlepl_PL
dc.identifier.doi10.3390/cancers13061394-
Appears in Collections:Artykuły (WNŚiT)

Files in This Item:
File Description SizeFormat 
Jazowiecka-Rakus_ Myxoma_virus_expressing_LIGHT_(TNFSF14).pdf3,45 MBAdobe PDFView/Open
Show simple item record


Uznanie Autorstwa 3.0 Polska Creative Commons License Creative Commons